PHILADELPHIA, Sept. 18, 2024 /PRNewswire/ — Alivia Analytics, a leading AI-powered healthcare data analytics and technology company, announced the expansion of its payment integrity solutions designed to help healthcare payers reduce payment errors and improve financial accuracy – backed by a powerful, configurable platform.
The offerings focus on key areas critical to ensuring payment integrity across the healthcare spectrum, which include:
The solutions are delivered as Tech-Enabled Services and Software as a Service (SaaS) that identify new recoveries missed by legacy vendors, deliver actionable pre- and post-payment analytics, and offer automated pre-payment corrections and savings.
“We are committed to addressing the most pressing challenges for healthcare payers,” said Michael Taylor MD, Chief Executive Officer of Alivia Analytics. “Our payment integrity solutions and modules are administered within the same analytics platform as our fraud detection modules, which makes for an efficient and unique system in the marketplace.”
Learn more about Alivia’s payment integrity solutions.
About Alivia Analytics
Alivia Analytics leverages responsible AI and healthcare claims expertise to help commercial and government health plans lower costs by avoiding fraud, waste, abuse, and overpayments, optimizing payment processes, and confidently making data-driven decisions. The powerful, configurable Alivia Platform provides adaptive pre- and post-payment flexibility with tech-enabled services and SaaS offerings that holistically address challenges in payment integrity, fraud detection and investigation case management, and data management. Alivia’s healthcare payer clients broaden ROI with increased operational efficiencies, decreased medical expense spending, bigger savings/recoveries, and lower provider and member abrasion. More information at aliviaanalytics.com
SOURCE Alivia Analytics
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…